TABLE 1.

Characterization of NL-r-HSAS pathogenesis in vivo^a

Implant type and no.	Days p.i.b	% CD4+/CD8+ cells	No. of HIV DNA copies/105 cells	% HSA+ cells	% Provirus expressionc
NL-r-HSAS infected
28	20	79	26	0.2	BGd
40	20	90	384	0.3	68
34	21	81	7,214	0.1	BG
36	21	67	5,911	1.1	19
39	21	68	5,058	1.8	35
19	22	58	1,240	0.7	60
20	22	90	1,197	0.8	64
33	22	57	897	0.5	58
16	23	73	34,468	3.0	9
15	23	81	6,000	1.8	30
2	24	85	3,324	1.9	58
5	24	85	3,424	1.3	39
8	24	83	5,846	2.5	43
30	27	62	39,458	2.5	6
28	27	34	45,300	7.1	16
34	28	83	1,106	0.1	BG
41	28	31	59,643	7.1	12
39	28	80	17,113	1.2	7
33	29	54	42,633	5.9	14
32	29	9	76,113	4.3	6
19	29	65	38,199	3.8	10
16	30	73	51,181	2.7	5
21	30	82	34,748	2.8	8
15	30	66	19,418	8.6	44
9	31	12	46,561	6.5	14
32	32	6	40,056	4.5	11
28	34	51	19,781	1.9	10
39	35	9	21,688	3.9	18
41	35	10	30,377	3.3	11
33	36	63	39,152	0.7	2
21	37	6	38,282	2.7	7
15	37	29	17,953	3.8	21
8	38	20	4,729	6.7	141
28	41	2	10,108	4.9	48
21	44	1	11,912	7.9	67
9	45	1	8,766	4.4	50
Mock infected
27	20	85	NDe	0.1
31	29	85	ND	<0.1
11	31	85	ND	0.2
31	36	81	ND	<0.1
11	38	81	ND	<0.1
31	43	70	ND	0.2
35	43	80	ND	<0.1

^aImplants from mice infected with NL-r-HSAS or mock infected were assessed by flow cytometry for CD4 and CD8 subset distribution of CD45⁺ thymocytes and for expression of murine HSA. Proviral burden was determined by quantitative PCR and is shown as copies of HIV DNA per 10⁵ cells. Percent provirus expression was calculated as described in Materials and Methods, assuming one provirus per cell. 

^bp.i., postinfection. 

^cPercent provirus expression was not calculated for mock-infected implants, since the levels of HSA in these implants are considered to be background. 

^dBG, HSA expression was not above the highest level of HSA expression (0.2%) observed in mock-infected implants. 

^eND, not detectable.